Recent developments in human immunodeficiency virus-1 latency research.
Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4(+) memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host, but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.
MRC-University of Glasgow Centre for Virus Research, Bearsden Road, Glasgow G61 1QH, UK.
Chi Ngai
CN
Chan
MRC-University of Glasgow Centre for Virus Research, Bearsden Road, Glasgow G61 1QH, UK.
Isabelle
I
Dietrich
MRC-University of Glasgow Centre for Virus Research, Bearsden Road, Glasgow G61 1QH, UK.
Margaret J
MJ
Hosie
MRC-University of Glasgow Centre for Virus Research, Bearsden Road, Glasgow G61 1QH, UK.
Brian J
BJ
Willett
D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008954:Models, Biological; D014775:Virus Activation / Q000187:drug effects; D017735:Virus Latency / Q000187:drug effects
D019380:Anti-HIV Agents